- Design
- prospective longitudinal single-arm study, no comparator
- Population
- 28 pseudophakic Indian eyes with mild to moderate primary open-angle glaucoma
- Primary outcome
- intraocular pressure and number of antiglaucoma medications at 18 months
- Effect
- pressure 21.14 (SD 2.18) to 15.14 mmHg (SD 1.51), P < 0.0001; medications 2.07 to 1.18, P < 0.05
Most published experience with trabecular micro-bypass stents comes from implantation combined with cataract surgery, which makes the pressure fall hard to attribute. This prospective Indian series implanted stents as a standalone procedure in 28 pseudophakic eyes with mild to moderate primary open-angle glaucoma, so the eye had already had its cataract removed and the stent is the only variable.
Mean pressure fell from 21.14 mmHg (SD 2.18) before surgery to 15.14 mmHg (SD 1.51) at 18 months (P < 0.0001), and the mean number of antiglaucoma medications from 2.07 (0.73) to 1.18 (0.83) (P < 0.05). A drop of about 6 mmHg with roughly one fewer drop, sustained to a year and a half, is a clinically meaningful result in this severity band.
The limitations are the ones that always attach to a series of this size. Twenty-eight eyes, no control arm, and no randomisation means the pressure fall cannot be separated from regression to the mean — eyes are operated on when the pressure is high, and high readings tend to be followed by lower ones regardless. Nor is there a comparison against simply adding or optimising a drop, which is the alternative a clinician is actually choosing between.
What the series does contribute is Indian denominators. Device evidence generated elsewhere leaves open whether the result transfers to eyes and health systems here, and a prospective local series at 18 months is worth more to an Indian surgeon deciding whether to offer the procedure than a larger foreign trial. It is a reason to consider the option, not yet a reason to prefer it.
- Consider a standalone trabecular micro-bypass stent in a pseudophakic eye with mild to moderate disease inadequately controlled on drops
- Set expectations at roughly one fewer medication rather than medication freedom; the mean was 1.18 drops at 18 months
- Weigh the procedure against optimising or adding a topical agent, the comparison this series does not make
- Treat the pressure fall as uncontrolled; regression to the mean cannot be excluded in a single-arm series of 28 eyes
- Discuss cost explicitly — the device is a recurring consumable cost against a recurring drop cost
Why it matters
Device evidence is almost all generated elsewhere and combined with cataract surgery, which is not the decision an Indian surgeon faces.
Don't overread it
A single-arm series of 28 eyes cannot show the device caused the pressure fall, or that it beats adding a drop.
The statistics, in plain English
With 28 eyes and no comparison group, a before-and-after difference cannot be attributed to the device: patients are selected for surgery when their pressure is at its highest, and the next reading tends to be lower whatever is done, which is regression to the mean. The very small standard deviations after surgery (1.51 mmHg) suggest a tightly selected group rather than a general population. A P value below 0.0001 confirms the pressures differ before and after; it says nothing about why.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free